Jim Saulnier & Associates LLC Invests $752,000 in Novo Nordisk A/S (NYSE:NVO)

Jim Saulnier & Associates LLC purchased a new position in Novo Nordisk A/S (NYSE:NVO) in the third quarter, HoldingsChannel reports. The firm purchased 6,314 shares of the company’s stock, valued at approximately $752,000.

A number of other institutional investors also recently made changes to their positions in the stock. Advisor OS LLC lifted its stake in Novo Nordisk A/S by 0.6% during the second quarter. Advisor OS LLC now owns 13,972 shares of the company’s stock valued at $1,994,000 after purchasing an additional 82 shares during the last quarter. Cascade Financial Partners LLC lifted its stake in Novo Nordisk A/S by 2.3% during the second quarter. Cascade Financial Partners LLC now owns 3,801 shares of the company’s stock valued at $543,000 after purchasing an additional 84 shares during the last quarter. Novare Capital Management LLC lifted its stake in Novo Nordisk A/S by 3.2% during the third quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock valued at $325,000 after purchasing an additional 85 shares during the last quarter. AA Financial Advisors LLC lifted its stake in Novo Nordisk A/S by 3.2% during the second quarter. AA Financial Advisors LLC now owns 2,805 shares of the company’s stock valued at $400,000 after purchasing an additional 86 shares during the last quarter. Finally, Steel Grove Capital Advisors LLC lifted its stake in Novo Nordisk A/S by 2.3% during the second quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company’s stock valued at $541,000 after purchasing an additional 86 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Up 2.4 %

NVO stock opened at $105.06 on Friday. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15. The company’s 50 day simple moving average is $115.48 and its 200-day simple moving average is $128.80. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The firm has a market capitalization of $471.46 billion, a P/E ratio of 34.00, a P/E/G ratio of 1.32 and a beta of 0.42.

Wall Street Analysts Forecast Growth

NVO has been the subject of several recent research reports. BMO Capital Markets cut their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.